Teladoc Health, Inc. provides business-to-business virtual health care services in the United States and internationally. The company is headquartered in Purchase, New York.
| Revenue (TTM) | $2.49B |
| Gross Profit (TTM) | $1.72B |
| EBITDA | $64.56M |
| Operating Margin | -5.68% |
| Return on Equity | -13.00% |
| Return on Assets | -3.22% |
| Revenue/Share (TTM) | $13.93 |
| Book Value | $7.21 |
| Price-to-Book | 0.94 |
| Price-to-Sales (TTM) | 0.50 |
| EV/Revenue | 0.602 |
| EV/EBITDA | 6.96 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -4.00% |
| Shares Outstanding | $181.68M |
| Float | $180.51M |
| % Insiders | 0.70% |
| % Institutions | 86.24% |
Volatility is currently contracting
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Teladoc Health shares fell more than 28% after the Company reported Q2 2026 revenue of $606.9 million and cut its full-year 2026 revenue guidance. Levi & Korsinsky investigates.
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Teladoc Health reported Q2 2026 revenue of $606.9 million against consensus estimates of $615 million to $628 million -- and the stock fell almost 30% in a single session. Levi & Korsinsky is investigating on behalf of TDOC investors who lost money Teladoc Health reported Q2 2026 revenue of $606.9 million against consensus estimates of $615 million to $628 million -- and the stock fell almost 30% in a single session. Levi & Korsinsky is investigating on behalf of TDOC investors who lost money
NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare is the former president and chief operating officer of Verisk Analytics, a strategic data analytics and technology partner to the global insurance industry. He will serve on the board's Audit & Compensation committees.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Teladoc Health projected its BetterHelp division to decline 7% to 0.5%. Following a quarter that featured a 12% annual decline, the Company is now telling investors to expect up to a 19% full-year revenue growth decline.
TDOC tops adjusted earnings estimates despite a revenue miss, as Integrated Care and international growth help cushion BetterHelp weakness and a lower 2026 outlook.
Teladoc Health Inc (NYSE:TDOC) is plunging today after the virtual healthcare provider reported second-quarter revenue of $606.9 million, missing Wall Street's estimate of $615.4 million, and lowered its full-year revenue guidance.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TDOC and any ticker you trade — then tracks every position and per-strategy win rate.
